RELMADA THERAPEUTICS, INC. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Relmada Therapeutics, Inc. (Nasdaq: RLMD) on July 28, 2026. The report discloses a material corporate event pursuant to Regulation FD.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a personnel appointment and does not contain financial statements or performance data.
Material Changes
The primary material change reported is the appointment of Bipin Dalmia, PhD, MBA, as the Company's Chief Business Officer. This announcement was made via a press release issued on July 28, 2026.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, outlook, or specific risk factors. The press release regarding the appointment is furnished as Exhibit 99.1 and is explicitly deemed "furnished" rather than "filed" for purposes of Section 18 of the Exchange Act, meaning it is not subject to the liabilities of that section nor incorporated by reference into other filings.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for details on Dr. Dalmia's background and specific responsibilities.
- Confirm the effective date of the Chief Business Officer appointment.
- Review subsequent filings for any financial impact or strategic shifts resulting from this leadership change.